Schering-Plough has agreed to pay $165m to settle a class action lawsuit that claims the company’s failure to disclose manufacturing deficiencies defrauded investors.
Pandemic influenza vaccine manufacturing technology will be made available to developing countries through a collaboration between the WHO and Schering-Plough.
German pharmaceutical firm Schering is planning to close down half
its production facilities in the coming years as it strives to
boost profitability and growth to a level that will beat its peers
in the industry, reports Phil Taylor.
Germany drugmaker Schering is planning to reduce its headcount by
1,250 with most of the cuts coming in production. The company is
blaming increased cost pressures due to European and international
competition.
Scottish start-up PharmaImaging will begin providing gamma
scintigraphy imaging services to companies involved in Phase I drug
development in early 2004, with PET facilities coming on-line later
that year.
Schering has been granted approval throughout the European Union
for Angeliq (oestradiol and drospirenone), its new low-dose hormone
replacement therapy.